Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

AIMS: Veliparib is a potent inhibitor of poly(ADP‐ribose) polymerase (PARP) enzyme. The objectives of the analysis were to evaluate the effect of baseline covariates and co‐administration of topotecan plus carboplatin (T + C) on pharmacokinetics of veliparib in patients with refractory acute leukaem...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Mehrotra, Shailly, Gopalakrishnan, Mathangi, Gobburu, Jogarao, Greer, Jacqueline M., Piekarz, Richard, Karp, Judith E., Pratz, Keith, Rudek, Michelle A.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5510066/
https://ncbi.nlm.nih.gov/pubmed/28156017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13253
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados